
Last updated: 2026-09-16 11:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Gyre Therapeutics, Inc. (GYRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6,69, with a market capitalisation of $709,37M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5,44 to $9,42. This page covers its latest market performance, valuation, price trends and company information.
$709,37M | |
$6,69 | |
$30,40 | |
$5,44 | |
$6,69 | |
33,00 | |
79,89K | |
-- | |
$9,42 | |
$5,44 | |
-- | |
-- |
Gyre Therapeutics, Inc. (GYRE) is trading at $6,69 in pre-market trading as of 2026-09-16 08:55:00, down 0,07% ($0,01) from the previous close of $6,69
Pre-market trading shows how investors are pricing GYRE before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Gyre Therapeutics, Inc. (GYRE) moved from $6,86 to $6,69, representing a decline of 2,55% ($0,18).
The stock traded between $6,41 and $7,27 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 108,06 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 31,3%
GYRE is currently trading at $6,69, placing it 31,3% of the way from its 52-week low of $5,44 to its 52-week high of $9,42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 618 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Gyre Therapeutics, Inc. (GYRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.